Selection procedure reference: EMA/TR/11363
Deadline for applications: 06 May 2026 23:59 CET
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in Amsterdam. It began operating in 1995. It is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
This traineeship opportunity is now open for applications until 06 May 2026 23:59 CET, with an intake on 1 October 2026.
About the traineeship programme
The Agency is looking for motivated, qualified recent graduates or students on an Erasmus+ or other programme or PhD students or Master's students (who posses a previous degree), who are interested in gaining experience and contribute to the Agency’s work for every patient in Europe. The purpose of a traineeship at the Agency is to perform tasks that are predominantly in the interest of the trainee’s training and principally serve to increase the trainee’s knowledge and to gain relevant experience.
Placement description
We are looking for a trainee in the Translational Sciences Office.
Specific objectives and projects
This traineeship will offer the successful candidate the opportunity to strengthen knowledge and expertise in non-clinical development and the 3Rs (Replacement, Reduction, Refinement) at EMA, and to interact with the Non-Clinical Working Party (NcWP), the 3Rs Working Party and the EU regulatory network.
The trainee will evaluate the needs for non-clinical development for severely debilitating and life-threatening diseases (SDLT). This will involve collecting data from marketing authorisation applications and scientific advice procedures to gather necessary information. The succesful candidate will also review recently published guidelines and recommendation papers for opportunities to streamline programs for SDLT.
The trainee will present the findings of the research at EMA and deliver a report analysing regulatory trends and precedents emerging from EMA procedures on non-clinical development programmes, with the aim of informing the NcWP drafting group preparing a reflection paper on SDLTs.
Learning outcomes
The trainee is expected to:
-
Gain an in-depth understanding of the European Medicines Agency’s (EMA) approach to assessment of the non-clinical dossier submitted by pharmaceutical companies when they seek marketing authorisation for their medicinal products.
-
Gain an understanding of the EMA's scientific advice procedures and how EMA experts advise applicants on critical aspects of a non-clinical devlopment development program.
-
Become familiar with regulatory requirements, agency processes, and regulatory practices related to medicinal products.
Eligibility criteria
To be eligible for consideration for this placement, you are required to:
-
enjoy full rights as a citizen of a European Union Member State or Iceland, Lichtenstein and Norway;
-
possess a university degree in Non-Clinical Pharmacology, Toxicology, Pharmacy, Biomedical Sciences, or any other Life Sciences (minimum of three years or more) that must have been obtained between 6 May 2025 and 6 May 2026 or be a university student on an Erasmus + or a similar programme or a PhD student or a Master's student with a previous fully finished degree in the areas mentioned before.
-
a thorough knowledge of English (at least level C1) and good knowledge of other official EU language (at least B2) of the Common European Framework for Languages
For criteria 1 and 2, you will be required to provide proof in the application form and at the interview stage. Failing to present these documents may result in the disqualification from the procedure.
Additional skills
In addition to the eligibility criteria, you will have:
-
Analytical skills and communication skills.
-
Good understanding of Non-Clinical Pharmacology and Toxicology.
-
Understanding of, and/or experience in, the 3Rs (Replacement, Reduction, Refinement) is considered beneficial.
Behavioural Competencies
You will demonstrate the following behavioural competencies:
Conditions of traineeship
The traineeship is offered for 10 months (1 October 2026 – 31 July 2027) and takes place at the Agency’s premises in Amsterdam with possibility for teleworking up to 40% of working time from The Netherlands and occasional teleworking from outside The Netherlands. Traineeships are offered for either full-time or part-time (80% or 50%) if combined with university studies.
The Agency pays a monthly stipend of €2,049.77 for a full-time traineeship (reduced accordingly for 80% or 50%) and a travel contribution upon joining the Agency.
Each trainee will have a mentor at the Agency who will guide the trainee through the programme.
The conditions of employment are stated in the Executive Decision on rules governing the traineeship programme at the EMA available here .
Expected selection timelines
Deadline for applications
06 May 2026 23:59 CET
Assessments (remote)
From mid-June 2026 to mid-July 2026
Decision and offers
By end of July 2026
Placement start
1 October 2026
Domenico Scarlattilaan 6 - 1083 HS Amsterdam - The Netherlands
Telephone +31 (0)88 781 6000 - Email recruitment@ema.europa.eu
© European Medicines Agency, 2024. Reproduction is authorised provided the source is acknowledged.